Immunome Inc (IMNM NASDAQ) stock market data APIs
$23.7195
-0.03(-0.1%)
as of July 6, 2026
Try our APIs with
free plan!
Immunome Inc Financial Data Overview
Price chart is built with
Anychart
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Prev. Close
23.7195
Open
23.6938
High
24.4011
Low
23.0841
52 wk Range
7.96-27.65
Market Cap
2 674 M
Shares Outstanding
113 M
Revenue
4 015 K
EPS
0
Beta
2.074
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunome Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunome Inc data using free add-ons & libraries
Get Immunome Inc Fundamental Data
Immunome Inc Fundamental data includes:
- Net Revenue: 4 015 K
- EBITDA: -226 350 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.591
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunome Inc News
New
4 Biotech Stocks Investors Should Watch in 2026
The biotech industry has navigated the uncertain macroeconomic environment effectively so far this year. Upbeat first-quarter results, new drug approvals and positive clinical and pipeline development...
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
BOTHELL, Wash., May 27, 2026--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced ...
What Offers Immunome (IMNM) a Compelling Investment Opportunity?
Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. During the fir...
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors
Immunome, Inc. (NASDAQ:IMNM) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. On April 29, Immunome, Inc. (NASDAQ:IMNM) reported the filing of a new drug appli...
Get Immunome Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
